CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks Real-Life impact of CIDP drug on 200 patients
Disease control Recruiting nowThis study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over two years to see how well the drug works in real…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Sponsor: argenx • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
New hope for nerve disease: experimental drug targets stubborn CIDP
Disease control Recruiting nowThis study tests an experimental drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't responded to standard treatments. The goal is to see if the drug can improve disability scores compared to a placebo over 48 weeks. Par…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New CIDP drug trial offers hope for nerve damage relief
Disease control Recruiting nowThis study tests a new drug called empasiprubart for adults with CIDP, a condition that causes nerve damage and weakness. About 160 people will receive either the drug or a placebo for 6 months, then everyone gets the drug for 2 more years. The goal is to see if it improves disab…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Engineered immune cells take on multiple sclerosis and more in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, to calm overactive immune attacks in people with relapsed or hard-to-treat neurological autoimmune diseases like multiple sclerosis, myasthe…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Phase: EARLY_PHASE1 • Sponsor: Tianjin Huanhu Hospital • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Sound waves could spot nerve disease earlier
Knowledge-focused Recruiting nowThis study looks at whether ultrasound can detect nerve changes in people with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Researchers will compare ultrasound images with standard nerve tests to see if ultrasound helps diagn…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC